| Size | Price | Stock | Qty |
|---|---|---|---|
| 5mg |
|
||
| 10mg |
|
||
| 25mg |
|
||
| 50mg |
|
||
| 100mg |
|
||
| 250mg |
|
||
| Other Sizes |
|
Purity: ≥98%
| Targets |
HSF1 (Kd = 160 nM)
|
|---|---|
| ln Vitro |
DTHIB (5 μM; 48 hours) treatment of C4-2 cells results in accumulation in the G1 phase and cell cycle arrest. C4-2 PCa cells enter senescence when DTHIB is stimulated[1].
DTHIB (0.5-5 μM; 48 hours) treatment decreases the steady-state protein abundance of the bona fide HSF1 targets molecular chaperones P23, HSP27, HSP70, and HSP90 in C4-2 cells[1]. DTHIB has an effect that is dose-dependent in reducing the clonal expansion of PC-3 and C4-2 PCa cells, with EC50 values of 3.0 μM and 1.2 μM, respectively[1]. DTHIB (0.5-10 μM) dose-dependently reduces the strong acute heat shock induction of the HSP70 and HSP25 molecular chaperones in mouse embryonic fibroblasts (MEFs). By lowering the steady-state transcript abundance of several molecular chaperones, DTHIB attenuates the heat shock response[1]. |
| ln Vivo |
DTHIB treatment (5 mg/kg; intraperitoneal injection; daily; for 3 weeks) potently inhibits the growth of tumors in a C4-2 xenograft mouse model[1].
|
| Cell Assay |
The HSF1 target gene expression in C4-2 Scr and shHSF1 cells treated for 36 hours with 2.5 μM DTHIB is assessed using qRT-PCR.
|
| Animal Protocol |
Nude mice (6 weeks of age) injected with C4-2 cells
5 mg/kg Intraperitoneal injection; daily; for 3 weeks |
| References |
| Molecular Formula |
C13H9CLFN3O3
|
|---|---|
| Molecular Weight |
309.6814
|
| Exact Mass |
309.031
|
| Elemental Analysis |
C, 50.42; H, 2.93; Cl, 11.45; F, 6.13; N, 13.57; O, 15.50
|
| CAS # |
897326-30-6
|
| Related CAS # |
897326-30-6
|
| PubChem CID |
108866909
|
| Appearance |
Light yellow to yellow solid powder
|
| Density |
1.6±0.1 g/cm3
|
| Boiling Point |
347.2±42.0 °C at 760 mmHg
|
| Flash Point |
163.8±27.9 °C
|
| Vapour Pressure |
0.0±0.8 mmHg at 25°C
|
| Index of Refraction |
1.700
|
| LogP |
4.48
|
| Hydrogen Bond Donor Count |
2
|
| Hydrogen Bond Acceptor Count |
4
|
| Rotatable Bond Count |
2
|
| Heavy Atom Count |
21
|
| Complexity |
385
|
| Defined Atom Stereocenter Count |
0
|
| SMILES |
O=C(NC1C=C([N+](=O)[O-])C(Cl)=CC=1)NC1C=CC(F)=CC=1
|
| InChi Key |
DWVIOMKFHSRQQM-UHFFFAOYSA-N
|
| InChi Code |
InChI=1S/C13H9ClFN3O3/c14-11-6-5-10(7-12(11)18(20)21)17-13(19)16-9-3-1-8(15)2-4-9/h1-7H,(H2,16,17,19)
|
| Chemical Name |
1-(4-chloro-3-nitrophenyl)-3-(4-fluorophenyl)urea
|
| Synonyms |
DTHIB
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO: 86~100 mg/mL (277.7~322.9 mM)
Ethanol: ~17 mg/mL (~54.9 mM) |
|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: 2.08 mg/mL (6.72 mM) in 10% DMSO + 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), clear solution; with sonication.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 20.8 mg/mL clear DMSO stock solution to 900 μL of 20% SBE-β-CD physiological saline solution and mix evenly. Preparation of 20% SBE-β-CD in Saline (4°C，1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution. (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 3.2291 mL | 16.1457 mL | 32.2914 mL | |
| 5 mM | 0.6458 mL | 3.2291 mL | 6.4583 mL | |
| 10 mM | 0.3229 mL | 1.6146 mL | 3.2291 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
|
|
|
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
COA
